Maya Khalil - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Maya Khalil

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

Journal for Immunotherapy of Cancer|January 26, 2019

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJeffrey M Conroy, Sarabjot Pabla, Mary K Nesline, et al.

Journal of the National Comprehensive Cancer Network : JNCCN|November 13, 2024

NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024John A Thompson, Bryan J Schneider, Julie Brahmer, et al.

The New England Journal of Medicine|March 1, 2023

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.

Pageof 3

Search research articles

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

Journal for Immunotherapy of Cancer|January 26, 2019

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJeffrey M Conroy, Sarabjot Pabla, Mary K Nesline, et al.

Journal of the National Comprehensive Cancer Network : JNCCN|November 13, 2024

NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024John A Thompson, Bryan J Schneider, Julie Brahmer, et al.

The New England Journal of Medicine|March 1, 2023

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.

Pageof 3